Re: Biomedical Publications Profile and Trends in Gulf Cooperation Council Countries

por Mikhailidis, Dimitri P
Publicado 2012

Epicardial fat: a novel marker of subclinical atherosclerosis in clinical practice?

por Katsiki, Niki, Mikhailidis, Dimitri P.
Publicado en Anatol J Cardiol (2017)

Hyperuricaemia in Cardiovascular Diseases: A Passive or an Active Player?

por Katsiki, Niki, Mikhailidis, Dimitri P.
Publicado en Med Princ Pract (2015)

Endocan and Erectile Dysfunction

por Balta, Sevket, Mikhailidis, Dimitri P.
Publicado en Am J Mens Health (2019)

Perivascular adipose tissue in cardiovascular diseases

por Katsiki, Niki, Mikhailidis, Dimitri P.
Publicado en Anatol J Cardiol (2020)

Diabetes and carotid artery disease: a narrative review

por Katsiki, Niki, Mikhailidis, Dimitri P.
Publicado en Ann Transl Med (2020)

Ciprofibrato na prevenção primária : controle das hiperlipidemias.

por Lewis, Barry, Mikhailidis, Dimitri P.
Publicado 1998.

Patient with Hypertriglyceridemia, Type 2 Diabetes, and Chronic Kidney Disease Treated with Atorvastatin and Omega-3 Fatty Acid Ethyl Esters

por Athyros, Vasilios G, Mikhailidis, Dimitri P
Publicado 2012

Half a century and more of PhD theses by published papers: Comment on: “Bringing the doctoral thesis by published papers to the Social Sciences and the Humanities: A quantitative e...

por Breimer, Lars H., Mikhailidis, Dimitri P.
Publicado en Scientometrics (2020)

Obstructive sleep apnea and cardiovascular disease: Is mean platelet volume one of the links?

por Papanas, Nikolaos, Mikhailidis, Dimitri P., Steiropoulos, Paschalis
Publicado en Anatol J Cardiol (2016)

Leptin, cardiovascular diseases and type 2 diabetes mellitus

por Katsiki, Niki, Mikhailidis, Dimitri P, Banach, Maciej
Publicado en Acta Pharmacol Sin (2018)

Is type 2 diabetes mellitus a coronary heart disease equivalent or not? Do not just enjoy the debate and forget the patient!

por Katsiki, Niki, Banach, Maciej, Mikhailidis, Dimitri P.
Publicado en Arch Med Sci (2019)

Lipid-lowering therapy and renin-angiotensin-aldosterone system inhibitors in the era of the COVID-19 pandemic

por Katsiki, Niki, Banach, Maciej, Mikhailidis, Dimitri P.
Publicado en Arch Med Sci (2020)

CETP inhibition in the REVEAL trial: could we aim higher?

por Sahebkar, Amirhossein, Mikhailidis, Dimitri P., Banach, Maciej
Publicado en Arch Med Sci (2020)

More Good News on Statins and COVID-19

por Katsiki, Niki, Banach, Maciej, Mikhailidis, Dimitri P
Publicado en Am J Cardiol (2021)

Assessing renal function – searching for the perfect marker continues!

por Nair, Devaki R., Mehta, Shweta, Mikhailidis, Dimitri P.
Publicado 2011

Estimated Glomerular Filtration rate (eGFR): A Serum Creatinine-Based Test for the Detection of Chronic Kidney Disease and its Impact on Clinical Practice

por Jain, Anjly, Mikhailidis, Dimitri P., Nair, Devaki R.
Publicado 2012

Dysfunctional high-density lipoprotein: not only quantity but first of all quality?

por Agouridis, Aris P., Banach, Maciej, Mikhailidis, Dimitri P.
Publicado en Arch Med Sci (2015)

A Comparison of the Aldosterone‐blocking Agents Eplerenone and Spironolactone

por Karagiannis, Asterios, Athyros, Vasilios G., Mikhailidis, Dimitri P.
Publicado en Clin Cardiol (2009)

The Link Between Human and Transgenic Animal Studies Involving Postprandial Hypertriglyceridemia and CETP Gene Polymorphisms

por Kolovou, Genovefa D, Anagnostopoulou, Katherine K, Mikhailidis, Dimitri P
Publicado 2009